Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2- over-expressing cells, respectively [1]

Ana Maria Tari; Gabriel Lopez-Berestein

doi:10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K

Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2- over-expressing cells, respectively [1]

Ana Maria Tari, Gabriel Lopez-Berestein

Experimental Therapeutics

Research output: Contribution to journal › Letter › peer-review

33 Scopus citations

Original language	English (US)
Pages (from-to)	295-297
Number of pages	3
Journal	International journal of cancer
Volume	86
Issue number	2
DOIs	https://doi.org/10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K
State	Published - 2000

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K

Cite this

@article{399c0b4ee2424173b3245fec1a7e35b3,

title = "Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2- over-expressing cells, respectively [1]",

author = "Tari, {Ana Maria} and Gabriel Lopez-Berestein",

year = "2000",

doi = "10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K",

language = "English (US)",

volume = "86",

pages = "295--297",

journal = "International journal of cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2- over-expressing cells, respectively [1]

AU - Tari, Ana Maria

AU - Lopez-Berestein, Gabriel

PY - 2000

Y1 - 2000

UR - http://www.scopus.com/inward/record.url?scp=0034029237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034029237&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K

DO - 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K

M3 - Letter

C2 - 10738260

AN - SCOPUS:0034029237

SN - 0020-7136

VL - 86

SP - 295

EP - 297

JO - International journal of cancer

JF - International journal of cancer

IS - 2

ER -

Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2- over-expressing cells, respectively [1]

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this